Progestin-only contraception and venous thromboembolism

被引:29
作者
Blanco-Molina, M. A. [2 ]
Lozano, M. [3 ]
Cano, A. [4 ]
Cristobal, I. [5 ]
Pallardo, L. P. [6 ]
Lete, I. [1 ]
机构
[1] Hosp Univ Araba, Dept Gynecol, Vitoria 01004, Alava, Spain
[2] Hosp Reina Sofia, Dept Med, Cordoba, Spain
[3] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[4] Hosp Pesset, Dept Gynecol, Valencia, Spain
[5] Hosp Zarzuela Madrid, Dept Gynecol, Madrid, Spain
[6] Hosp La Paz, Dept Endocrinol, Madrid, Spain
关键词
FACTOR-V-LEIDEN; DEPOT-MEDROXYPROGESTERONE ACETATE; ORAL-CONTRACEPTIVES; HORMONAL CONTRACEPTIVES; INHERITED THROMBOPHILIA; INTRAUTERINE-DEVICE; PROTHROMBIN G20210A; PULMONARY-EMBOLISM; THROMBOTIC RISK; PROTEIN-S;
D O I
10.1016/j.thromres.2012.02.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combined oral contraceptives (COC) are the most popular contraceptive method in developed countries. Since their introduction there have been numerous changes and modifications in its composition with the aim to improve safety and tolerability while maintaining contraceptive efficacy. Most of the changes have been conducted on the progestin component, since most of the combinations include ethinyl estradiol as oestrogen. One of the adverse effects of COC is the increased risk of venous thromboembolism (VTE) in two clinical forms of presentation: deep vein thrombosis or pulmonary embolism. This review details the changes in haemostasis induced by progestin-only contraceptives and the risk of VTE in women who utilize this type of contraception; the relationship with other risk factors such as thrombophilia; the interactions of these contraceptives with anticoagulant treatment and finally the eligibility criteria for the use of hormonal contraception in women with previous VTE or thrombophilia carriers. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:E257 / E262
页数:6
相关论文
共 53 条
[1]  
[Anonymous], 2004, MED EL CRIT CONTR US, VThird
[2]  
Aznar J, 2000, HAEMATOLOGICA, V85, P1271
[3]   Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study [J].
Barsoum, Michel K. ;
Heit, John A. ;
Ashrani, Aneel A. ;
Leibson, Cynthia L. ;
Petterson, Tanya M. ;
Bailey, Kent R. .
THROMBOSIS RESEARCH, 2010, 126 (05) :373-378
[4]  
Battaglioli T, 2007, CURR OPIN HEMATOL, V14, P488
[5]   Clinical profile of contraceptive progestins [J].
Benagiano, G ;
Primiero, FM ;
Farris, M .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2004, 9 (03) :182-193
[6]   Limited knowledge on progestogen-only contraception and risk of venous thromboembolism [J].
Bergendal, Annica ;
Odlind, Viveca ;
Persson, Ingemar ;
Kieler, Helle .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2009, 88 (03) :261-266
[7]   Venous thromboembolism in women using hormonal contraceptives [J].
Blanco-Molina, Angeles ;
Trujillo-Santos, Javier ;
Tirado, Raimundo ;
Canas, Inmaculada ;
Riera, Antoni ;
Valdes, Mariano ;
Monreal, Manuel .
THROMBOSIS AND HAEMOSTASIS, 2009, 101 (03) :478-482
[8]   Progestogen-only contraception in women at high risk of venous thromboembolism [J].
Conard, J ;
Plu-Bureau, G ;
Bahi, N ;
Horellou, MH ;
Pelissier, C ;
Thalabard, JC .
CONTRACEPTION, 2004, 70 (06) :437-441
[9]  
CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319
[10]   Thrombophilias in adolescents: the past, present and future [J].
Dietrich, Jennifer E. ;
Hertweck, S. Paige .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2008, 20 (05) :470-474